SRSF2 and acquired polycythemia vera: Building upon high-throughput sequencing data from collaborative studies between Mayo Clinic, Rochester, USA and University of Florence, Italy, an integrated genetic and clinical survival risk model for PV (MIPSS-PV) was developed, that included SRSF2 mutations, age >67 years, thrombosis history and leukocytosis (≥15×109/L) as independent risk factors for reduced overall survival, whereas no unique mutation profile was associated with an increased risk for thrombosis [7].